Breaking News

AbbVie, Galapagos Extend Collaboration

May 17, 2013

To include Crohn's disease in GLPG0634 program

Galapagos NV and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase II program in Crohn's disease, and upon successful completion, AbbVie will pay Galapagos $50 million. AbbVie will be responsible for funding and performing clinical development beyond Phase II, as well as regulatory and commercialization activities.
 
"AbbVie supports the start of this innovative study in Crohn's disease with GLPG0634. Our experience within gastroenterology, combined with a novel alternative treatment for this disease may provide a greater benefit to patients in the future," said Scott Brun, M.D., vice president, pharmaceutical development, AbbVie.
 
"Galapagos and AbbVie are moving forward with GLPG0634, expanding the scope of the development program into inflammatory bowel disease. The innovative Phase II program in Crohn's disease is designed to move rapidly into Phase III when successful," said Onno van de Stolpe, chief executive officer of Galapagos. "Galapagos is in a strong financial position to fund the Crohn's program, in addition to a Phase IIb program with GLPG0634 in RA."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers